Skip to content

Clinical study on individualized hydration regimen based on non-invasive cardiac output measurement system to prevent contrast-induced acute kidney injury

Clinical study on individualized hydration regimen based on non-invasive cardiac output measurement system to prevent contrast-induced acute kidney injury

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120203
Enrollment
Unknown
Registered
2026-03-10
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-Induced Acute Kidney Injury

Interventions

Experiment Group:The experimental group, which received the individualized high-volume hydration regimen, had its hydration rate determined based on dynamically measured EDFR levels: when EDFR was les
when EDFR was between 50% and 67%, the rate was 1.5 ml/kg/h
and when EDFR was greater than 67%, the rate was 1 ml/kg/h, maintained until 12 to 24 hours after surgery.
Control Group:The control group, which received the standard hydration regimen, was infused with normal saline at a rate of 1 ml/kg/h 6 to 12 hours before the injection of contrast medium and maintain

Sponsors

Zhongda Hospital Affiliated to Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Volunteer to participate in this trial and sign the informed consent form; 2. Aged >=18 and = 6; 5. Non-invasive cardiac output measurement 6 hours before surgery shows EDFR < 50%; 6. Volunteer to participate in this trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Allergic to contrast medium or having received contrast medium within 7 days; 2. Patients with existing or suspected acute kidney injury; 3. Pregnant or breastfeeding individuals; 4. Patients who require regular hemodialysis, peritoneal dialysis, other renal replacement therapies, unilateral nephrectomy, or kidney transplantation; 5. Those who have taken aminoglycosides, aristolochic acids, cisplatin, or other nephrotoxic drugs within one week before enrollment; 6. Patients with acute heart failure, severe infectious diseases, connective tissue disease, liver failure, tumors, sudden cardiac death, etc.

Design outcomes

Primary

MeasureTime frame
Incidence of Contrast-Induced Acute Kidney Injury;

Secondary

MeasureTime frame
Major Adverse Cardiovascular Event;Major Adverse Kidney Event;

Countries

China

Contacts

Public ContactGaoliang Yan

Department of Cardiology, Zhongda Hospital Affiliated to Southeast University

yanshipingguo@163.com+86 187 6189 0380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026